7AA Preclinical + Parent Human Data
N-Acetyl Semax
Russia-born ACTH-fragment peptide with dual terminal protection — sharper focus, BDNF surge, and neuroprotection that outlasts unmodified Semax by 30+ minutes.
In Plain English:
N-Acetyl Semax Amidate (NASA) is the most chemically fortified variant of Semax, a heptapeptide analogue of ACTH(4-10) developed by the Institute of Molecular Genetics, Russian Academy of Sciences. Two structural upgrades — acetylation at the N-terminus and amidation at the C-terminus — shield both ends of the chain from aminopeptidases and carboxypeptidases, significantly extending plasma stability compared to parent Semax. The compound crosses the blood-brain barrier via intranasal olfactory nerve transport, rapidly elevates BDNF and TrkB expression in the hippocampus, activates melanocortin (MC3R/MC4R), dopaminergic, and serotonergic pathways, and chelates copper ions implicated in amyloid-beta aggregation. Community reports consistently describe heightened focus, motivation, and a clean stimulant quality without euphoria or rebound.
Research Maturity
Preclinical + Parent Human Data (~160+ PubMed papers on parent Semax; only 1 directly on N-acetyl Semax variant+ Studies)
Focus
Cognition
Mood / Stress
Neuroprotection
Origin
Developed at the Institute of Molecular Genetics, Russian Academy of Sciences, Moscow. Parent compound Semax (Met-Glu-His-Phe-Pro-Gly-Pro) was derived from ACTH fragment 4-10 and first described in 1991. The Pro-Gly-Pro C-terminal tripeptide was added to inhibit carboxypeptidase degradation; N-acetylation then added further N-terminal protection. Semax received Russian Ministry of Health approval in 1994 for cerebrovascular indications (ischemic stroke, cognitive impairment, optic nerve disease). The fully modified NASA variant remains a research compound outside Russia, with no FDA/EMA approval.
Mechanism
1. BBB penetration via intranasal olfactory/trigeminal nerve transport (CNS peak ~45-60 min post-dose; estimated intranasal CNS bioavailability 60-70%). 2. Agonist activity at melanocortin receptors MC3R and MC4R, modulating neuroplasticity, stress response, and neuroprotection. 3. Rapid upregulation of BDNF protein (1.4-fold) and mRNA exon III (3-fold), plus TrkB phosphorylation (1.6-fold) and mRNA (2-fold) in rat hippocampus (Dolotov et al., Brain Research, 2006; PMID 16996037). 4. Activation of dopaminergic and serotonergic systems. 5. High-affinity Cu(II) chelation (conditional Kd 1.3×10⁻¹⁵ M at pH 7.4), stripping copper from Aβ complexes and suppressing Aβ fibrillogenesis and ROS production by up to 90% (Sciacca et al., ACS Chem Neurosci, 2022; PMID 35080861). 6. Metabolised to Pro-Gly-Pro (PGP), itself biologically active with prolonged brain-tissue half-life, explaining once/twice-daily dosing efficacy despite short parent plasma half-life. 7. N-terminal acetylation specifically alters Cu(II) coordination geometry (CuN₃O chromophore vs CuN₂OS in unmodified Semax), modifying redox potential and cytoprotective profile (Magrì et al., J Inorg Biochem, 2016; PMID 27586814).
Outcome
Parent Semax human evidence: stroke RCT (N=110) — improved neurological deficit scores; chronic brain ischemia trial (N=30) — 71% vs 41% memory accuracy vs control; fMRI cognitive enhancement study (N=24). Animal (Alzheimer's model, transgenic APPswe/PS1dE9 mice): both Semax and derivative reduced cortical amyloid plaques 2.8-fold and hippocampal plaques 2.6-fold vs untreated; effects persisted 1.5 months post-treatment (Radchenko et al., Acta Naturae, 2025; PMID 41479572). N-Acetyl Semax Amidate specifically: no dedicated RCTs; pharmacokinetic modelling shows ~30-minute extension of stability vs unmodified Semax due to terminal protection. Community N: hundreds of documented intranasal reports noting focus, motivation, reduced anhedonia, improved memory consolidation.
